13 Nov

The Impact of Connected Devices on Medication Adherence

Sean Glynn, M.S., is the Director of HEOR and Strategic Initiatives for HealthBeacon in North America

Zara Fullerton Kinsella, Medical Doctor, is the Medical Science Liaison for HealthBeacon

A physician recently described an interaction where a patient was ending a course of therapy due to a poor response to treatment. The patient asked, “What should I do with the leftover medication I have at home?”  The doctor replied, “I thought you said you were taking all of your medication.  Why do you have leftover medication?”

This is not an isolated event. One out of every two patients fail to take their medication as directed and have stopped treatment within a twelve-month period. For those of us familiar with the medication non-adherence problem, this is not surprising. Hippocrates was known to have said, “Keep a watch also on the faults of the patients, which often make them lie about the taking of things prescribed.”

Our generation is asking for connected devices to be a positive force for change in every aspect of health support, and adherence is no exception. The health and technology industries are making multi-billion dollar investments so that connected devices can fundamentally transform the delivery of healthcare. Technology offers a wide variety of solutions from smart packaging to robotic dispensers, the Internet of Things offers connected devices that monitor when medicine is unpackaged and even when a used needle is disposed into a smart sharps container. Mobile technology can remind and reward patients to help them stay on track with their medication and software platforms convey, synthesize and prioritize cohort data for clinicians. In addition, artificial intelligence can offer insights into big data and predict required interventions before a patient becomes symptomatic.

Getting health data from patients has challenged the industry to innovate. Our approach at HealthBeacon has been to use the Internet of Things to passively track what the patient is already doing, in this case, disposing of a used pen or syringe into a sharps container. By capturing this behavior and relaying the information to patients, caregivers and physicians, a key data point is created. This collection of data on a real-time basis can serve to increase patient engagement, lead to more informed clinical decision making and ultimately enable the early identification of patients who may benefit from interventions that focus on improving adherence.

If this patient had been in possession of an adherence monitoring device, their story would have been very different. Any missed doses of medication would have immediately been identified and shared with their healthcare provider or caregiver, enabling them to receive the support they need to maximize outcomes from their treatment.

Connected devices have the potential to identify and support those patients who need the most help with managing their medication. Given the magnitude of this group, these technologies have a transformative role to play in improving patient care and enriching the relationship between physicians, patients and caregivers.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

13 Nov

HealthBeacon appoints Sean Glynn as first Director of HEOR, and Dr. Zara Fullerton Kinsella as first Medical Science Liaison

HealthBeacon appoints first Director of HEOR and hires first Medical Science Liaison.

(Dublin, Ireland; Boston, MA, – November 13th, 2019) Leading medication adherence technology company, HealthBeacon has announced the appointments of Sean Glynn as Director of Health Economics and Outcomes Research, and Dr. Zara Fullerton Kinsella as Medical Science Liaison.

Sean Glynn, Director of HEOR, joined the HealthBeacon team three years ago with the critical role of launching HealthBeacon’s operations in the US. Sean’s background in behavioral sciences and his deep understanding of the medication adherence issue will be instrumental in furthering HealthBeacon’s mission to improve patient outcomes by delivering new adherence solutions to patient’s who self-administer injectable medications in their homes. Sean is based out of HealthBeacon’s Boston office.

Dr. Zara Fullerton Kinsella has joined the HealthBeacon team as a Medical Science Liaison, to facilitate clinical research and assist with Regulatory Affairs. Zara is a medical doctor with an undergraduate degree in Business and Economics at Trinity College. Her keen interest in healthcare led her to study Graduate Entry Medicine at University College Cork. As a junior doctor, she worked in a variety of medical specialties. Zara is based out of HealthBeacon’s office in Dublin, Ireland.

These appointments will further HealthBeacon’s commitment to evidence-based decision making and program design. “We are excited to expand our team and add these critical capabilities with Sean being promoted to Director of HEOR and Dr. Zara joining the team as our Medical Science Liaison” said Jim Joyce, CEO of HealthBeacon, “these roles will bring through our latest studies, data projects and provide important medical insights into product development.”

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication at home. HealthBeacon’s FDA cleared smart sharps bin tracks patient injection history, provides personalized interactive reminders and safely stores used injectables. With the intervention of HealthBeacon’s Smart Sharps Technology, patients’ persistence and adherence increased by 25-30% within twelve months of initiating therapy. The HealthBeacon integrated model connects a patient’s routine and the prescribing clinician’s workflow. This technology has been adopted across thirteen countries with >300,000 injections tracked since launch in 2014, with a patient acceptance rate of
80-90%.

 

HealthBeacon’s Medical Science Liaison Dr. Zara Fullerton Kinsella

HealthBeacon’s HEOR Sean Glynn

Media Enquiries: Mary Principe  | Email: events@healthbeacon.com

18 Sep

HealthBeacon reveals strategic investors in Asia and the US, SGInnovate and Manatt Health

HealthBeacon, a medication adherence technology company based in Dublin receives investment from international strategic partners, SGInnovate and Manatt. 

(Dublin, Ireland; Singapore, – September 18th, 2019) Dublin and Boston based digital health company, HealthBeacon announces that SGInnovate (Singapore) and Manatt (USA) have become strategic investors in HealthBeacon as part of the final completion of the Series A fundraising announced in January. The total Series A fundraising was $12M bringing the total funding into the company of $15M.

Jim Joyce, Co-Founder, and CEO of HealthBeacon said, “We are delighted to have SGInnovate and Manatt on board as investors and strategic partners will assist us significantly as we bring our medical adherence technology to patients in the Asian and USA markets.”

HealthBeacon continues its expansion plan into the Asian Market. Hsien-Hui Tong, SGInnovate’s Head of Venture Investing said, “Medical non-adherence places a significant burden on healthcare systems. HealthBeacon’s use of Smart Tools to tackle this global challenge resonates well with SGInnovate’s belief in investing in best-in-class Deep Tech tackling difficult problems faced around the world. The team has shown a proven track record in improving care for patients with chronic medical conditions in Europe, the US, and Canada. SGInnovate is proud to join in as a strategic investor to help with the company’s expansion into Asia. This also marks our first healthcare investment together with Enterprise Ireland. We look forward to supporting more promising Deep Tech startups globally.”

Hsien-Hui Tong of SGInnovate. Image: SGInnovate

Lisa Suennen, Leader of Manatt said, “HealthBeacon has a proven team that is tackling a challenging and unaddressed problem in a new way. Their solution is one that both helps patients directly and improves caregivers ability to help them manage difficult conditions. We are excited to support the company and watch it grow.”

Manatt leader Lisa Suennen. Image: Manatt

The addressable market for injectable medications has reached nearly $50 billion. As of today, HealthBeacon operates in 13 markets and has tracked more than 300,000 home-based injections making it one of the largest global deployments of a medical adherence device. Today HealthBeacon employs over 40 people and plans to continue its growth over the next 18 months.

The smart sharps bin system by HealthBeacon has made it easier for patients, using injectable medications, to stay on track with their treatment schedule. This has resulted in improved patient medication adherence and driving patient care.

About SGInnovate:

SGInnovate is a private limited company wholly owned by the Singapore Government. With the support of our partners and co-investors, we back deeply technical founders through equity-based investments, access to talent, and support in building customer traction. Our efforts are prioritised around transformational technologies such as Artificial Intelligence, Quantum Tech, and MedTech, which represent impactful and scalable answers to global challenges.

About Manatt:

Manatt is an integrated professional services firm that provides strategic consulting and legal support to large and small companies.  Manatt has transformed from one of the top law firms to an industry-leading, integrated professional services firm that combines its legal capabilities with deep strategic, analytics and public policy capabilities through Manatt Health and its digital and technology businesses. Manatt Health’s interdisciplinary teams are known for engaging in leading-edge thought leadership, often working with the major healthcare foundations to develop new thinking on complex healthcare issues.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

22 Jul

U.S. Growth Hormone Adherence Patient Survey Results

Study finds that patients on growth hormone medications have difficulty adhering to their medication schedule

HealthBeacon and The MAGIC Foundation announce discoveries from a patient survey

(Boston,MA; July 16th, 2019) HealthBeacon, a medication adherence technology company, and The MAGIC Foundation, the world’s leading advocacy and information group for human growth disorders, have carried out a survey which highlights the adherence issues for patients on growth hormone medication.

Poor adherence to treatment of chronic diseases is a worldwide problem and adherence to long-term therapy for chronic illnesses in developed countries is averaging 50%. The survey highlighted a trend towards poor adherence over duration of treatment with an important drop after the first year. Across all demographics surveyed, the top reason for the patient missing their medication was due to “being too busy and forgetting”.

HealthBeacon’s Director of Operations for North America, Sean Glynn said, “It was interesting to note that one-in-five patients are self-reporting suboptimal adherence levels, highlighting the need for smart tools and support to help stay on track with treatment.” Smart Tools such as the HealthBeacon smart sharps bin system has made it easier for patients, using injectable medications, to maintain their treatment schedule and this has resulted in improved persistence to treatment by 20-30% within the first year.

“This is an important look into the challenges associated with long-term treatment for chronic conditions such as growth disorders,” commented Dianne Kremidas, Executive Director at The MAGIC Foundation. “We are delighted to share these results with patients, physicians and pharmaceutical companies to bring light to this critical issue.”

The MAGIC Foundation is the global leader in endocrine health, advocacy, education, and support. HealthBeacon believes that engaging with the world’s leading advocacy groups will provide a strong network and patient engagement program to improve medication adherence.

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule and uses customized reminders to help them start and stay on track with medication. The technology has been on the market since 2013 and has tracked > 270,000 injections and is now available in the US Market. To learn more, email events@healthbeacon.com.

About The MAGIC Foundation

The MAGIC Foundation was incorporated in the state of Illinois and received 501(C)3 non-profit status October 29, 1989. Since its inception, the Foundation has grown to include support services for adults who were also impacted by these disorders.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

12 Jun
10 Jun

Partnership Announcement with Bionical – JUNE 2019

HealthBeacon signs agreement with leading UK provider of technology-enabled healthcare services, Bionical Solutions.

HealthBeacon partners with Bionical Solutions to offer a digitally connected Patient Support Programme in the UK

(Dublin IE, London UK- June 10th, 2019) HealthBeacon, a medication adherence technology company, announced today their partnership with Bionical Solutions, a leading patient support provider in the UK market, to provide smart tools for managing medication and a connected platform to patients across the UK.

This exciting partnership will combine HealthBeacon’s smart technology together with a targeted outreach patient support programme that will significantly improve patient adherence delivering a truly digitally connected Patient Support Programme.

HealthBeacon has developed the world’s first smart sharps bin for tracking patient adherence to chronic injectable medication. The smart sharps bin provides patients with an easy, elegant, safe, and connected way to dispose of their used injections. The smart sharps unit has been globally validated by regulatory authorities and pharma and is launched in 13 markets.

Prof. Doug Veale, Consultant Rheumatologist stated: “The HealthBeacon technology has had a profound impact in helping my patients adhere to their medication schedule”.

Poor adherence to treatment of chronic diseases is a worldwide problem of striking magnitude with adherence to long-term therapy for chronic illnesses in developed countries averaging 50%.  The smart sharps bin system has made it easier for patients, using injectable medications, to stay on track with their treatment schedule. This has resulted in improved persistence to treatment by 20-30% within the first year.

HealthBeacon’s CEO, Jim Joyce commented “The signing of this partnership is a major milestone in making our technology accessible to patients in the UK.  HealthBeacon is delighted to partner with Bionical, an industry leader in patient support programmes.

Bionical’s CEO Helen Miles added “We look forward to partnering with HealthBeacon in the UK market.  Our focus is on patient care and having a digitally connected platform and tool that will drive actionable insights will lead to a more targeted patient outreach programme and will bring enormous value to patient care across the UK”.

About HealthBeacon

HealthBeacon is a medication adherence technology company which develops smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule and uses customized reminders to help them start and stay on track with medication. The technology has been on the market since 2014 and has tracked > 250,000 injections in the home and is now available in the UK Market.

About Bionical

Bionical Solutions is a leading provider of technology enabled healthcare services to pharmaceutical, biotech, healthcare companies and the NHS. Bionical delivers personalised HCP and patient experiences through the optimal blend of human interactions and technology to transform and optimise experience and improve outcomes.

Media enquiries: Mary Principe  | Email: events@healthbeacon.com

10 Jun

HealthBeacon innovation featured as part of MedTechWeek

HealthBeacon featured as part of the MedTechWeek publication in the Irish Independent reflecting on our eHealth Innovation of the year award from the Irish Medtech Association. Hear from CTO Kieran Daly on how the award impacted HealthBeacon and the wider plans as the organisation continues to scale.

Click on the link below to see the article & read the interview.

Innovation in Medtech

09 May

HealthBeacon Labs shortlisted for design award

We are very excited to announce that the HealthBeacon User Experience Lab has been shortlisted for the UX 2019 Awards in the UX Achievement in Health and Lifestyle category.

We have achieved 90% patient acceptance rates with our current product, which we firmly believe is a testament to our patient-centric design ethos. To embed this across our organisation we created the User Experience Lab. An immersive experience where one can step into the shoes of a patient, empathise and understand their needs. This Lab will ensure we maintain this ethos as we design and release new products and will also help our clients truly understand the challenges that their patients are facing.

Karen Tracey

Product Designer

 

 

03 May

Malin Johansson to become Vice President of Europe for HealthBeacon

Malin Johansson to become Vice President of Europe for HealthBeacon

Dublin, Ireland Headquartered, HealthBeacon, a leading global medical adherence technology provider whose mission is to “build smart tools for managing medications” will be establishing a dedicated European division to drive further growth of its technology platform. It’s FDA cleared “best in class” medical adherence tool for tracking injectable medications has already been globally launched in 11 countries. This new division will be responsible for all European markets outside of the UK and Ireland and we are delighted to announce that Malin Johansson will be heading up this group. In her role as Vice President of Europe she will be responsible for developing both the market and the HealthBeacon organisation across this important region.

 

“We have known Malin for years from her impressive career in Pharmaceuticals working for Abbott/AbbVie in both Medical Device, Patient Experience and Marketing functions with Affiliate, Nordic, Europe and Global responsibilities and we couldn’t be more excited to work with her again. Malin is a passionate evangelist for implementing technology and solutions that make a real difference in patients’ lives and has extensive experience specifically implementing digital health solutions in Europe.”

Jim Joyce, CEO and Co-founder, HealthBeacon

 

“I am delighted to be joining this innovative, fast growing technology company with a clear mission to support people that requires to take mediciations home and Health Care systems around the world with trusted information around medication adherence and consumption. Today, HealthBeacon has implemented it’s technology in a number of European countries; Germany, Portugal, Ireland, Netherlands, Belgium, and Italy. My ambition would be to rapidly expand the implementation and increase the number of countries we support in Europe to allow a wider access to HealthBeacon´s technology. In doing so, HealthBeacon will strenghten their existing business relationships and become a strategic and strong partner to support the expansion of future connected medicines.”

Malin Johansson, VP of Europe, HealthBeacon

Malin most recently was Senior Global Marketing Manager,  Immunology Strategic Operations, Global Marketing at AbbVie responsible for developing and implementing the AbbVie Immunology leadership identity for their portfolio of assets  and for driving adoption of technology and marketing solutions across the world. She will work between Paris and Stockholm, while covering all of Europe. Outside of work Malin is an active mom and a passionate soccer fan with her club being the Swedish AIK where her two daughters play.

16 Apr

Future Pharma Leader Network 2019

Dave Shanahan sets up a Future Pharma Leader Network 2019 Dinner Series hosted at HealthBeacon Headquarters.

Who is Dave Shanahan, by Jim Joyce: When I think of Pharmaceutical Leadership in Ireland one name jumps to everyone’s short list, Dave Shanahan. Dave went from a Janssen medical  sales representative to becoming the Managing Director Manager of Pfizer Ireland during the days when category leading medication, Lipitor, was redefining the industry. He lead IDA’s global Life Sciences division, became a top executive for AbbVie out of Chicago, is the founding chair of the Irish government’s Health Innovation Hub and today sits on the board of Enterprise Ireland. HealthBeacon is lucky to have him heading Partnership Initiatives since our founding in 2013. Dave is a high energy, personable connector of ideas and people in healthcare and is certainly a leader.

What is the Future Pharma Leader Network 2019?  It’s a small network of people working in the Pharmaceutical industry who have been selected by their bosses as Future Pharma Leaders.

Dave, in your words tell us more? “One of the joys of looking back on a long pharma career is reflecting on some great people and presentations along the way which enabled new thinking and new friendships. Many Irish leaders are in the vanguard of the changes presently sweeping healthcare and pharma. Think of the convergence of pharma, medtech, digital tech and healthcare services, the rise of genomics and digital health, new economic realities impacting demographics and cost. Pharma’s business model is facing profound challenges and opportunities.

So, we’ve decided to host some evening events for an exclusive group of Pharma executives we’re calling the Future Pharma Leader Network. We’re bringing terrific speakers to address our network and engage with them on topics which are disrupting healthcare today”

Who is invited? We reached out to Ireland’s current Pharma Leaders in the commercial divisions of the major pharmaceutical companies and asked each of them to nominate people who they thought were Future Pharma Leaders. We received 34 nomination with contributions from almost every major pharmaceutical company that has a presence in Ireland. Unfortunately, we couldn’t accommodate everyone so our final list is 25 highly talented ambitious pharma executives.

Who is speaking at the inaugural event? One of Ireland’s great healthcare innovators the legendary Professor Brendan Buckley. His resume includes: Chief Medical Officer Tekro, Former Chief Medical Officer of ICON, Co-founder Firecrest, Consultant Endocrinologist, Chairperson Fighting Blindness, Clinical Professor University College of Cork, and a great speaker!

Can you tell us about future speakers? We have a great list in development, we want people with a unique perspective on the Pharma industry and a proven track record of success, who are willing to share their perspective with talented emerging pharma execs. Think exciting Biotech CEOs, Proven Health and Tech Innovators, Ministers, Pharma Execs with International Careers, Payors, Health System Leaders…

Why set this up? We believe these 25 nominees are capable of defining the pharmaceutical industry in Ireland and abroad. We wanted to give them a space to interact with each other over a meal, hear a great thought provoking speaker and critically discuss the opportunities and changes that will affect the Pharmaceutical industry.

Will you run this event outside of Ireland? That’s the plan, but let’s run this one first.

Is this event open to anyone? No, you must be nominated to attend the event and we are keeping it small to allow people a chance to interact with each other.

© 2015 Health Beacon - Privacy Policy - Website by Medusa